PAVmed Inc., a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a strategic business update, outlining near-term strategic priorities and resource reallocation.

Prostatype Genomics said on Monday that it has formed a commercialization alliance for its gene-based prostate cancer test with Swedish genetic testing provider Life Genomics.

Recently, Chengdu Qi Tan Technology Co., Ltd. announced that it had completed the financing round C of 700 million CNY. This round of financing was led by Mei Tuan Capital, and the Capital Great Health Fund managed by HG Capital and BioTrack Capital continued to make additional investments.